Iago Pinal-Fernandez
Affiliations: | National Institutes of Health,Bethesda |
Area:
Myositis, Dermatomyositis, Polymyositis, Inclusion Body Myositis, Myopathies, Methodology, Statistics, Bioinformatics, EpidemiologyGoogle:
"Iago Pinal-Fernandez"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Torres-Ruiz J, Pinal-Fernandez I, Selva-O'Callaghan A, et al. (2024) Nailfold capillaroscopy findings of a multicentric multi-ethnic cohort of patients with idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology. 42: 367-376 |
Walitt B, Singh K, LaMunion SR, et al. (2024) Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. Nature Communications. 15: 907 |
Pinal-Fernandez I, Muñoz-Braceras S, Casal-Dominguez M, et al. (2024) Pathogenic autoantibody internalization in myositis. Medrxiv : the Preprint Server For Health Sciences |
Kleefeld F, Horvath R, Pinal-Fernandez I, et al. (2024) Multi-level profiling unravels mitochondrial dysfunction in myotonic dystrophy type 2. Acta Neuropathologica. 147: 19 |
Lloyd TE, Michelle EH, Pinal-Fernandez I, et al. (2023) Author Response: Clinical Subgroups and Factors Associated With Progression in Patients With Inclusion Body Myositis. Neurology. 101: 500 |
Muñoz-Braceras S, Pinal-Fernandez I, Casal-Dominguez M, et al. (2023) Identification of Unique microRNA Profiles in Different Types of Idiopathic Inflammatory Myopathy. Cells. 12 |
Pinal-Fernandez I, Milisenda JC, Pak K, et al. (2023) Transcriptional derepression of CHD4/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies. Annals of the Rheumatic Diseases |
Sherman MA, Pak K, Pinal-Fernandez I, et al. (2023) Anti-Sp4 autoantibodies co-occur with anti-TIF1 and are associated with distinct clinical features and immunogenetic risk factors in juvenile myositis. Arthritis & Rheumatology (Hoboken, N.J.) |
Mammen AL, Amato AA, Dimachkie MM, et al. (2023) Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. Rheumatology. 5: e67-e76 |
Pinal-Fernandez I, Quintana A, Milisenda JC, et al. (2023) Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis. Annals of the Rheumatic Diseases |